Clinical Response to Seribantumab, an Anti–Human Epidermal Growth Factor Receptor-3 Immunoglobulin 2 Monoclonal Antibody, in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma Harboring an <i>NRG1</i> FusionSubotheni Thavaneswaran, David M. Thomas, Valerie M. Jansen et al.|JCO Precision Oncology|2022Cited by 8
Genomic Therapy Matching in Rare and Refractory CancersFrank P. Lin, Emily Collignon, Anthony Glover et al.|JAMA Oncology|2026Cited by 6
A signal-seeking phase 2 study of Trastuzumab emtansine in tumours harbouring HER2 amplification or mutationSubotheni Thavaneswaran, David M. Thomas, Frank Lin et al.|npj Precision Oncology|2024Cited by 6
Genomic therapy matching in rare and refractory cancers: Updated results from a retrospective cohort study in the Molecular Screening and Therapeutic (MoST) program.Frank Lin, David M. Thomas, Subotheni Thavaneswaran et al.|Journal of Clinical Oncology|2023Cited by 2
Trastuzumab emtansine (T-DM1) in advanced cancers with <i>HER2 </i>mutations or amplification: Results from the Molecular Screening and Therapeutics (MoST) Program substudy.Subotheni Thavaneswaran, David M. Thomas, Antony Mersiades et al.|Journal of Clinical Oncology|2023Cited by 2